Nolla Health's AI-Issued Prescriptions for Acne Care

Every prior AI-prescribing pilot in the US, including an earlier Utah program from a company called Doctronic, only let AI approve refills of medication a human doctor had already prescribed ^[5]. Nolla Health's Utah pilot does something categorically different: its Nolla Derm app can generate a brand-new, initial prescription for acne treatment without a doctor ever signing off first, making it the first organization in the US authorized by a state regulator to do so ^[1]. That earlier Doctronic refill pilot had already triggered friction: Utah's own Medical Licensing Board publicly called for the program's suspension in 2026, saying it had not been consulted and that it put patients at risk ^[5]. Nolla's team has said it proactively engaged that same licensing board ahead of its launch, suggesting the company treated the earlier clash as a lesson rather than a one-off ^[6]. Utah also waived its normal requirement that a prescriber hold a medical license specifically to allow this pilot to proceed ^[6].

The AI's autonomy is explicitly temporary and conditional, following a step-down schedule written into the pilot. For the program's first 100 patients, two separate Utah-licensed physicians must independently review and approve every single AI-generated prescription before it reaches a pharmacy ^[4]. Once the program scales past 100 and up to 500 patients, the AI is allowed to issue prescriptions directly, with physicians only auditing them retrospectively on a weekly basis ^[4]. Beyond 500 patients, human review drops further still, to a monthly spot-check of at least 10 percent of prescriptions plus a mandatory review of every escalation or adverse-event case ^[4]. That three-stage ramp-down is formalized in the signed agreement between Nolla's operating entities and Utah's Office of Artificial Intelligence Policy and Division of Professional Licensing, which runs for an initial 12-month term and can be renewed for up to two additional 12-month periods ^[3]. Utah has been careful to frame this as experimentation, not endorsement: the state's own sandbox language states that participation 'does not mean the State of Utah has approved, endorsed, certified, or vouched for the product' ^[8].

The pilot's economics are explicit by design. A traditional in-person dermatology visit can cost up to $300, while the Nolla Derm pilot costs $4.99 a month, itself a discount off a $9.99 normal price, plus $10 to $50 for the medication itself ^[1]. That price gap is aimed at a documented care gap: more than 80 percent of US counties are classified as healthcare deserts, affecting over 120 million people ^[7]. In Utah specifically, roughly 100,000 residents have active acne, but only about 10 percent ever see a dermatologist, the average wait time for an appointment is 61 days, nearly double the 32.3-day national median, and 11 of the state's counties have no dermatologist at all ^[1][7]. Those numbers are the explicit justification Nolla and Utah regulators have pointed to for allowing an AI system to do something no software had been permitted to do in the US before this launch.

The launch has reopened a fight that didn't start with Nolla. After the earlier Doctronic refill pilot, Utah's Medical Licensing Board had already accused the state's AI office of moving without proper consultation ^[5]. Now the American Medical Association has weighed in directly: its CEO, John Whyte, has publicly said AI tools should not autonomously practice medicine ^[6]. That institutional alarm is spreading beyond Utah: the Federation of State Medical Boards has formed a national workgroup specifically to help other state medical boards figure out how to regulate AI tools performing clinician functions, a response directly prompted by Utah's clash ^[9]. Utah's AI office, its medical board, the FSMB, and the FDA are now in direct conversation about next steps, which means this single acne pilot could end up shaping how every state handles autonomous AI prescribing going forward ^[10].

Nolla's AI does not have free rein even within its narrow lane. It can only select from a pre-approved formulary of eight topical treatments, including tretinoin, adapalene, and clindamycin with benzoyl peroxide, and only for mild-to-moderate acne ^[2]. The system is built to hard-stop and hand off to a human physician for severe acne, pregnancy or breastfeeding, immunosuppression, serious kidney or liver disease, prior adverse medication reactions, minors, failed identity verification, or any address outside Utah ^[1]. Nolla's chief medical advisor, Dr. Zaid Fadul, frames this as the core safety argument: 'The AI can't improvise. It can only choose from a short list of physician-approved topical treatments.' ^[2]Even so, the guardrails don't erase every risk cited around the launch: reporting alongside the pilot has flagged that image-based AI diagnostic systems can misread skin conditions on darker skin tones with substantially lower accuracy, raising concern that a visual-first triage tool could widen, rather than close, existing healthcare disparities even as it expands access on paper ^[11].